TheraRadar
← Back
Data updated: May 30, 2026

BEDFORD

Generics

BEDFORD is a generic drug manufacturer focused on Oncology, Infectious Disease, Dermatology.

1982
Since
25
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

BEDFORD's Key Drugs

BEDFORD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

BEDFORD's Recent FDA Approvals

New NDA/BLA approvals for BEDFORD over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BEDFORD's Therapeutic Areas

BEDFORD's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 33%
2 drugs
Infectious Disease 17%
1 drugs
Dermatology 17%
1 drugs
Gastroenterology 17%
1 drugs
Cardiovascular 17%
1 drugs

BEDFORD Pipeline Snapshot

Active clinical trials for BEDFORD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling